View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 17, 2020updated 12 Jul 2022 11:57am

Blueprint Medicines reports positive data from trial of avapritinib

Blueprint Medicines has reported positive data from the Phase II PIONEER trial evaluating avapritinib in patients with indolent systemic mastocytosis (SM).

Blueprint Medicines has reported positive data from the Phase II PIONEER trial evaluating avapritinib in patients with indolent systemic mastocytosis (SM).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Avapritinib (AYVAKIT) is a kinase inhibitor designed to selectively bind and inhibit D816V mutant KIT, which acts as a major cause for SM in about 95% of patients.

Part 1 of the study observed that subjects treated with avapritinib showed a statistically significant mean decline of about 30% in total symptom score (TSS) at 16 weeks, as measured by the Indolent SM Symptom Assessment Form (ISM-SAF).

Consistent improvements across objective measures of mast cell burden and patient-reported quality of life were noted in subjects treated with avapritinib.

Avapritinib was found to be well-tolerated, with no patients discontinuing treatment due to adverse events.

Blueprint Medicines chief medical officer Andy Boral said: “Avapritinib was specifically designed to inhibit D816V mutant KIT, with the goal of delivering transformative benefit to patients.”

“In indolent SM, these placebo-controlled data are the first to show consistent clinical activity across multiple measures of disease, from mast cell burden to clinical outcomes and quality of life.”

Based on the results from Part 1 of the study, 25mg once daily (QD) is selected as the recommended Part 2 dose (RP2D) of the PIONEER Phase II trial.

Avapritinib is currently approved by the US Food and Drug Administration (FDA) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumour (GIST) harbouring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

Blueprint Medicines is working on the clinical development programme focused on the indication in advanced, smouldering and indolent SM, along with multiple areas of GIST treatment.

SM is a rare disease driven by the KIT D816V mutation. Anaphylaxis, pruritis, brain fog, maculopapular rash, bone pain and fatigue are among the associated symptoms of the disease.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena